Noveris Health Sciences is trading 11.76% down at CA$0.07, with the decline appearing primarily sector-driven amid weaker biotechnology sentiment.
- Biotech ETF XBI is down 2.11% following disappointing pelacarsen trial results from Ionis Pharmaceuticals and analyst downgrades.
- No new company-specific announcement was identified for September 16, 2026; the latest located filing was the September 9 annual-meeting results release.
- A market-data snapshot reported 334,793 shares traded.